Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD8421 + camizestrant + ribociclib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD8421 + camizestrant + ribociclib is an investigational **three-drug combination** being tested in clinical trials for the treatment of advanced or metastatic solid tumors, particularly **estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer**. - **AZD8421** is a highly selective **CDK2 inhibitor** developed to overcome resistance to CDK4/6 inhibitors. - **Camizestrant** (AZD9833) is an oral selective estrogen receptor degrader (**SERD**), acting by degrading and antagonizing estrogen receptor (ER) signaling. - **Ribociclib** (Kisqali) is an **oral CDK4/6 inhibitor**, which blocks cell cycle progression. The combination aims to enhance cell cycle inhibition and ER signaling blockade, potentially improving efficacy in patients whose disease is resistant to standard CDK4/6 inhibitors and endocrine therapies. The regimen is delivered orally in trial settings to female patients with advanced breast cancer or high-grade serous ovarian cancer[1][2][3][4][5][6][7][9][10].
- Other names
- AZD8421 + camizestrant + ribociclib
02
Targets
ER (Estrogen receptor)CDK6 (Cyclin-dependent kinase 6)CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on AZD8421 + camizestrant + ribociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD8421 + camizestrant + ribociclib.